The $7 billion (CY2021) company by revenues entered India a decade ago, but after couple of years of prospecting it decided last year to ac...

Glenmark Life Sciences, which was spun off from Glenmark Pharmaceuticals in 2019 to focus on the API business, posted revenue from operatio...

The firm has developed the API (active pharmaceutical ingredient) in house at its R&D centre here. Optimus Pharma has revealed highly promi...

As the threat of compulsory licence (CL) looms over big pharma in India, companies are rushing in to sign voluntary licensing agreements th...

"Natco Pharma is pleased to announce its registration approval given by Central Insecticide Board & Registration Committee (CIB&RC)... for ...

The presidential order issued on August 6 called for federal agencies involved in the procurement of essential medicines, medical counterme...

Piramal said it does not comment on market speculation, Lupin did not respond to ET’s query.

The drug maker said the audit of its API manufacturing plant at Miryalaguda in Telangana, by the US FDA, has been completed.

The resolution professional who is in charge of the management of the Chennai-based company has set April 25 as the fresh date for submitti...

The company had to sell assets to rein in debt. In 2012, it sold its penicillin business to US drug maker Hospira for $200 million.

The company is raising Rs 1,330 crore in the primary market. Proceeds of Rs 225 crore from the issue will be used to reduce debt on the com...

ET had reported in its May 27 edition that the two companies are in advanced talks for a possible transaction.

Bulk drugs, or active pharmaceutical ingredients (APIs), are the ingredients used to give a drug its therapeutic effect.

Sun Pharmaceutical announced it received approval from the US FDA for generic copies of Gleevec, a drug that treats chronic myeloid leukemi...

The buying of warrants by the promoter group of Sequent Scientific reflects their confidence in the business, points out Diwan.

The acquisition process is expected to be completed in the next 3 to 6 months, a release from Hyderabad-based Granules India said.

After spitting fire at Indian pharma sector's active pharma ingredients (APIs) makers, the Chinese dragon is now turning its wrath on India...